P65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts

Cancer Letters

Volumn 317, Issue 1, 2012, Pages 106-113

  Schulze, Jochen ^a   Weber, Kristoffer ^a   Baranowsky, Anke ^a   Streichert, Thomas ^a   Lange, Tobias ^a   Spiro, Alexander Simon ^a   Albers, Joachim ^a   Seitz, Sebastian ^a   Zustin, Josef ^a   Amling, Michael ^a   Fehse, Boris ^a   Schinke, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

IL 1B; Osteoblast; P65; Prostate cancer

Indexed keywords

INTERLEUKIN 1BETA; ONCOPROTEIN; SYNAPTOTAGMIN I;

ARTICLE; BIOTINYLATION; BONE BIOPSY; BONE METASTASIS; CANCER CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR DYNAMICS; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BONE NEOPLASMS; CELL LINE, TUMOR; CHEMOKINES; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOBLASTS; PARACRINE COMMUNICATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTOR RELA; TRANSFECTION; UP-REGULATION;

MURINAE;

EID: 84856349942     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.016     Document Type: Article

References (52)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol. Cancer Ther. 2007, 6:2609-2617.
3. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
4. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005, 328:679-687.
5. Casimiro S., Guise T.A., Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol. Cell. Endocrinol. 2009, 310:71-81.
6. Yang J., Fizazi K., Peleg S., Sikes C.R., Raymond A.K., Jamal N., Hu M., Olive M., Martinez L.A., Wood C.G., Logothetis C.J., Karsenty G., Navone N.M. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res. 2001, 61:5652-5659.
7. Soos G., Jones R.F., Haas G.P., Wang C.Y. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res. 1997, 17:4253-4258.
8. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17:16-23.
9. Schulze J., Albers J., Baranowsky A., Keller J., Spiro A., Streichert T., Zustin J., Amling M., Schinke T. Osteolytic prostate cancer cells induce the expression of specific cytokines in bone-forming osteoblasts through a Stat3/5-dependent mechanism. Bone 2010, 46:524-533.
10. Weber K., Bartsch U., Stocking C., Fehse B. A multicolor panel of novel lentiviral " gene ontology" (LeGO) vectors for functional gene analysis. Mol. Ther. 2008, 16:698-706.
11. Lessard L., Mes-Masson A.M., Lamarre L., Wall L., Lattouf J.B., Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. 2003, 91:417-420.
12. Sweeney C., Li L., Shanmugam R., Bhat-Nakshatri P., Jayaprakasan V., Baldridge L.A., Gardner T., Smith M., Nakshatri H., Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004, 10:5501-5507.
13. Su L., David M. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J. Biol. Chem. 2000, 275:12661-12666.
14. Vykhovanets E.V., Shukla S., MacLennan G.T., Resnick M.I., Carlsen H., Blomhoff R., Gupta S. Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate 2008, 68:34-41.
15. Vykhovanets E.V., Shukla S., MacLennan G.T., Vykhovanets O.V., Bodner D.R., Gupta S. Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation. Prostate 2009, 69:633-643.
16. Cheng C.Y., Hsieh H.L., Sun C.C., Lin C.C., Luo S.F., Yang C.M. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells. J. Cell. Physiol. 2009, 219:183-193.
17. Ashikawa K., Majumdar S., Banerjee S., Bharti A.C., Shishodia S., Aggarwal B.B. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J. Immunol. 2002, 169:6490-6497.
18. Liu D., Kim D.H., Park J.M., Na H.K., Surh Y.J. Piceatannol inhibits phorbol ester-induced NF-kappa B activation and COX-2 expression in cultured human mammary epithelial cells. Nutr. Cancer 2009, 61:855-863.
19. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43:1809-1818.
20. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978, 21:274-281.
21. Arend W.P. Interleukin-1 receptor antagonist. Adv. Immunol. 1993, 54:167-227.
22. Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J. Immunol. 1985, 135:2562-2568.
23. Lee Y.M., Fujikado N., Manaka H., Yasuda H., Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int. Immunol. 2010, 22:805-816.
24. Bubendorf L., Schöpfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum. Pathol. 2000, 31:578-583.
25. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
26. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4:540-550.
27. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., Wojno K., Snyder L.A., Yan L., Pienta K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007, 67:9417-9424.
28. Begley L.A., Kasina S., Mehra R., Adsule S., Admon A.J., Lonigro R.J., Chinnaiyan A.M., Macoska J.A. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
29. Singh S., Singh R., Sharma P.K., Singh U.P., Rai S.N., Chung L.W., Cooper C.R., Novakovic K.R., Grizzle L.E., Lillard J.W. Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett. 2009, 283:29-35.
30. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 2008, 8:837-848.
31. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732.
32. Jimi E., Nakamura I., Duong L.T., Ikebe T., Takahashi N., Rodan G.A., Suda T. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 1999, 247:84-93.
33. Lee S.K., Gardner A.E., Kalinowski J.F., Jastrzebski S.L., Lorenzo J.A. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 2006, 38:678-685.
34. Trebec D.P., Chandra D., Gramoun A., Li K., Heersche J.N., Manolson M.F. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J. Cell. Biochem. 2007, 101:205-220.
35. Trebec-Reynolds D.P., Voronov I., Heersche J.N., Manolson M.F. IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. J. Cell. Biochem. 2010, 109:975-982.
36. Polzer K., Joosten L., Gasser J., Distler J.H., Ruiz G., Baum W., Redlich K., Bobacz K., Smolen J.S., van den Berg W., Schett G., Zwerina J. Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum Dis. 2010, 69:284-290.
37. Kimble R.B., Vannice J.L., Bloedow D.C., Thompson R.C., Hopfer W., Kung V.T., Brownfield C., Pacifici R. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 1994, 93:1959-1967.
38. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1998, 2:706-709.
39. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 1996, 11:1043-1051.
40. Saijo S., Asano M., Horai R., Yamamoto H., Iwakura Y. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 2002, 46:533-544.
41. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., Ikuse T., Asano M., Iwakura Y. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 2000, 191:313-320.
42. Aksentijevich I., Masters S.L., Ferguson P.J., Dancey P., Frenkel J., van Royen-Kerkhoff A., Laxer R., Tedgård U., Cowen E.W., Pham T.H., Booty M., Estes J.D., Sandler N.G., Plass N., Stone D.L., Turner M.L., Hill S., Butman J.A., Schneider R., Babyn P., El-Shanti H.I., Pope E., Barron K., Bing X., Laurence A., Lee C.C., Chapelle D., Clarke G.I., Ohson K., Nicholson M., Gadina M., Yang B., Korman B.D., Gregersen P.K., van Hagen P.M., Hak A.E., Huizing M., Rahman P., Douek D.C., Remmers E.F., Kastner D.L., Goldbach-Mansky R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. New Engl. J. Med. 2009, 360:2426-2437.
43. Reddy S., Jia S., Geoffrey R., Lorier R., Suchi M., Broeckel U., Hessner M.J., Verbsky J. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. New Engl. J. Med. 2009, 360:2438-2444.
44. Lorenzo J.A., Naprta A., Rao Y., Alander C., Glaccum M., Widmer M., Gronowicz G., Kalinowski J., Pilbeam C.C. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinology 1998, 139:3022-3025.
45. Kitazawa R., Kimble R.B., Vannice J.L., Kung V.T., Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 1994, 94:2397-2406.
46. Angelucci A., Garofalo S., Speca S., Bovadilla A., Gravina G.L., Muzi P., Vicentini C., Bologna M. Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocr. Relat. Cancer 2008, 15:91-100.
47. Shiirevnyamba A., Takahashi T., Shan H., Ogawa H., Yano S., Kanayama H., Izumi K., Uehara H. Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. Brit. J. Cancer 2011, 104:505-513.
48. Lazennec G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:33-44.
49. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verástegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
50. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
51. Mantovani A., Savino B., Locati M., Zammataro L., Allavena P., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010, 21:27-39.
52. Kalliolias G.D., Liossis S.N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin. Invest. Drugs 2008, 17:349-359.